NCT06961682Not yet recruiting
Effectiveness of MD on MetS Patients
Effectiveness of MD on Patient With MetS to Control Hypertension, Diabetes ,Obesity and Dyslipidemia in Patients Attending Assiut University Hospital
Source: ClinicalTrials.gov · Last updated 8 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The metabolic syndrome (MetS), is a complicated condition linked to coronary artery disease.This group includes visceral obesity (abdominal or android type obesity), insulin resistance (IR), hypertension, and dyslipidaemia.The global prevalence of MetS is estimated to be about one-quarter of the world population or over a billion global citizens .A high MetS prevalence of 55% was found in Egyptians, 85.6% among diabetics, and 76.6% among hypertensive patients .People can modify their diet, physical activity, decrease smoking habits to lower their chance of developing MetS. Frequent exercise can lower blood pressure while increasing insulin sensitivity, lipolysis, and energy expenditure. It has the ability to improve blood lipid parameters .Diet is one of the most important tools available to improve MetS. However, the diet for the prevention and treatment of MetS remains unspecified beyond weight control and reduction in total calories. Several evidences show that it should generally be low in saturated fats, trans fats, cholesterol, sodium and simple sugars .The adherence to the Mediterranean Diet(MD) brings up two positive features, firstly the activity levels are increased and secondly the environmental impact becomes self-rewarding. The more the MD is favoured, the more the self-productivity is achieved resulting in a stronger life style adaptation .MD causes reduction of CVD incidence and outcomes decreases BP (systolic and diastolic) , inverses association with mortality,improvements in dyslexia, decreases incidence of T2DM.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 29 Apr 2025
- Start date
- 1 May 2025
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Assiut University
- Diseases
- Obesity, High blood pressure
- NCT number
- NCT06961682
What you commit to
- Study type: Interventional
- Planned participants: 170
- From 1 May 2025 to the primary completion date, 30 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria:
- All people diagnosed as metabolic syndrome
- (Hypertension(systolic BP≥130 or Diastolic BP ≥85)
- prediabetes fasting plasma glucose(100-125),oral glucose tolerance test(140-199)Hba1c(5.7-6.4)ADA
- Diabetes, fasting\>125, oral glucose tolerance test\>200, Hba1c≥6.5 ADA .
- Hyperlipidaemia(TG≥150 mg\\dl-HDL\<40 in male and \<50 in female) \[12\]
- Obesity(waist circumference ≥102cm in male and ≥88cm in female) \[12\]
- Exclusion criteria:
- Type 1 diabetes
- Patients with renal or advanced liver disease(Failure)
- Oral contraceptives, psychiatric, neurologic medications and steroid therapy
- Patients with heart failure and presence of stent
- Endocrine disease (Thyroid disease especially hypothyroidism-Cushing disease)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.